INTRODUCTION
lung cancer, NSCLC
LUNG CANCER, SKIN TOXICITY, NSCLC
The current standard of care for patients with advanced or metastatic non–small‐cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)‐activating mutations is treatment with EGFR‐tyrosine kinase inhibitors (TKIs). A meta‐analysis of randomized controlled trials with first‐generation EGFR‐TKIs (gefitinib or erlotinib) showed prolonged progression‐free survival (PFS) relative to chemotherapy in first‐line settings.In the ARCHER1042 study, preemptive treatment with doxycycline reduced skin toxicity of dacomitinib treatment.